Planet 13 Holdings Inc. (CSE: PLTH) (OTC: PLNHF) stock looks to be a good long term investment for cannabis investors. As a vertically-integrated company in the emerging cannabis market, it’s strategically positioned for growth. Interestingly, it was quite recently that the stock really jumped on to the radar and the one spark that fanned the flame is its statistics on the Las Vegas Cannabis Entertainment Complex.
Planet 13 Holdings Inc. Price Analysis
Planet 13 Holdings Inc. is headquartered in Las Vegas, Nevada and as of the press time, the stock price is 2.10 USD.
Steady but Strong Planet 13
The company has been performing well with some strong growth in its first two quarters of 2018. The firm is mainly focused on providing an array of international award-winning marijuana products as well as providing an unparalleled dispensary experience.
To ensure that Planet 13 Holdings comes on top, it has taken significant steps, for instance, phase two planned expansions are already underway.
New Production Facility
In early November, Planet 13 launched its first phase of 112,000 sq. Ft. cannabis entertainment complex near Las Vegas and a 16,200 square foot dispensary. The retail dispensary is the largest and most advanced in the world.
Besides, there’s also
The new facility is meant to enable Planet 13 to meet the rapidly growing demand for TRENDI concentrate as well as vape lines. Also, it’s for addressing the overwhelming demand for the company’s Medizin line. In general, the entire Phase II expansion is expected to cost about US$6 million.
Mike Tyson Deal
The company also signed an agreement with the cannabis venture of Mike Tyson (former heavyweight champion), where it became an exclusive launch alliance of Tyson Ranch products in Nevada.
It means that Tyson Ranch products are available in its superstore shelves.
By the Numbers
As it was expected, after opening the mega superstore, the company recorded an impressive number of customers per day last month with a total of 1,962 at an average ticket of $89.62.
According to Co-CEO of Planet 13, the results were meeting the 2000 customers per day at an average ticket of $75 that they guided to during the opening of the superstore. It should be clear that it’s only 35% of the square footage that has already been built.
Therefore, more visibility is expected to continue growing once the phase II expansion is complete.
Besides, Planet 13 had $5.49 million in revenue from the cannabis entertainment complex in Las Vegas. It means that the superstore revenue has now grown almost 63.4% from November and 13.1% compounded monthly rate.
Moreover, the latest record is that the superstore saw over 6,000 visitors with almost 3,500 paying customers and an average ticket of US$91.11
PLNHF is simply an exciting play coming into the cannabis space. With the new TRENDI brand as well as the superstore in Las Vegas strip as a base and recording new results each day, Planet 13 is only getting better.
Undoubtedly, Planet 13 is primed for growth as well as ready for the new markets as legalization for cannabis in the US continues. For a serious cannabis investor, PLNHF looks to be a must-own.
For the latest updates on PLNHF and the hottest MJ stocks, sign up below!
Disclosure: We have no position in PLNHF and have not been compensated for this article.
Image courtesy of Pexels
Decision Diagnostics Corp (OTCMKTS:DECN) Explodes On COVID-19 Test Kit Opportunity
Decision Diagnostics Corp (OTCMKTS:DECN) is exploding higher after unveiling a new methodology for the screening of coronavirus. GenViroTM COVID-19 screening kit is the latest catalysts fuelling the stock’s price action activity in the market. Similarly, the stock has rallied by more than 300% as investors take note of the huge opportunity up for grabs as the coronavirus pandemic continues to cause havoc.
OTCMKTS:DECN Price Analysis
The ever-growing demand for coronavirus test kit presents a unique opportunity for the company to generate significant value. In return, investors have continued to push the stock higher even as the broader equity market continues to plunge into the bear territory.
OTCMKTS:DECN is currently trading in a steep uptrend after succumbing to bearish pressure in 2019. Given the strength of the upward momentum, the stock is closing in on its one-year highs as the break out shows no signs of slowing down. A rally followed by a close above the $0.08 mark should open the door for bulls to push the stock to two-year highs.
Similarly, the $0.05 mark is the immediate support level above which the stock remains a bull play. Conversely, a breach of the support level would leave Decision Diagnostics susceptible to further drops, probably back to the $0.03 level. However, given the developments on the global scene, the stock looks set to continue powering high on pullbacks.
Decision Diagnostics bills itself…
Is CytoDyn Inc. (OTCMKTS:CYDY) A Buy?
CytoDyn Inc (OTCMKTS:CYDY) has been making big moves lately, which have propelled the stock from December low of $0.270 to new highs. Notably, CytoDyn’s surge has come on significant volume as well, a clear sign of strong investor interest in the stock.
The excitement in CytoDyn stock that we are witnessing right now comes as the company has taken a leading role in the fight against the deadly Wuhan coronavirus. Moreover, investors have started pouring on CytoDyn stock as the company advances the development of its lead drug candidate as a treatment for about two dozen different cancer types.
Before we delve into the details, here is a brief profile of CytoDyn for those investors who may have just come across this company for the very first time.
CytoDyn operates in the healthcare sector as a biotechnology company. It is engaged in developing innovative treatments for a broad range of medical indications. Its lead product candidate is leronlimab (PRO 140). Clinical trials of leronlimab are ongoing for conditions such as HIV and multiple cancers with impressive results already attained. But CytoDyn is expanding its target conditions with leronlimab in the wake of the outbreak of the Wuhan coronavirus.
Here are some of the recent developments at CytoDyn that have excited renewed investor interest in its stock.
CytoDyn’s leronlimab under consideration as Wuhan potential coronavirus treatment
CytoDyn’s lead drug candidate leronlimab (PRO 140)…
Rainmaker Worldwide Inc (OTCMKTS:RAKR) Looking For Bagholders
On the OTC Markets, there are a lot of pump and dumps. Investors need to protect themselves from these types of scams and one, in particular, is Rainmaker Worldwide Inc (OTCMKTS:RAKR).
OTCMKTS:RAKR Price Action
While the price action recently has been positive, it’s just a matter of time before RAKR is trading in the double zeros again. It’s not a question of if it will happen, but when it will happen.
About Rainmaker Worldwide
According to its profile, Rainmaker Worldwide Inc. is headquartered in Peterborough, Canada, with an innovation and manufacturing center in Rotterdam, Netherlands. Its patented water technology provides economical drinking water wherever it’s needed and at scale. Rainmaker builds two types of energy-efficient, fresh water-producing technologies to participate in this opportunity. 1. Air-to-Water, which harvests fresh water from humidity in the atmosphere. 2. Water-to-Water, which transforms seawater or polluted water into drinking water.
Lack of Fundamentals
The biggest concern facing investors is the lack of fundamentals. OTCMKTS:RAKR has a current market cap of $41 milli0n, but reported just $1000 in sales in the quarter ending September 30, 2019. Making matters worse is that Rainmaker burned through $524,000 in the quarter. Throughout its history, Rainmaker has lost $14.7 million.
EU Horizon 2020 Project and $2.5 million grant
Last September, Rainmaker touted the award of the European Union (EU) Horizon 2020 Project for Rainmaker’s Water to Water Product. According to the press…